Ausgabe 1/2020
Inhalt (15 Artikel)
American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019
Martin Chopra
2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10–14 December 2019
Martin Chopra
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Romain Cohen, Benoît Rousseau, Joana Vidal, Raphaël Colle, Luis A. Diaz Jr., Thierry André
Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review
Michele Porcu, Cinzia Solinas, Cristina Migali, Angelo Battaglia, Marina Schena, Lorenzo Mannelli, Alfredo Addeo, Karen Willard-Gallo, Luca Saba
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis
Lorena Alves Teixeira, Francisco Jose Candido dos Reis
Association Between Glutathione-S-Transferase Gene Polymorphisms and Responses to Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia: A Meta-analysis
Nari Lee, Su Min Park, Jeong Yee, Ha Young Yoon, Ji Min Han, Hye Sun Gwak
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Todd M. Bauer, Alice T. Shaw, Melissa L. Johnson, Alejandro Navarro, Justin F. Gainor, Holger Thurm, Yazdi K. Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
Seung Tae Kim, Jung Yong Hong, Jeeyun Lee, Joon Oh Park, Ho Young Lim, Won Ki Kang, Young Suk Park
Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study
Hidenori Kato, Paul de Souza, Sang-We Kim, Jason D. Lickliter, Yoichi Naito, Keunchil Park, Sanjeev Kumar, Ganesh M. Mugundu, Yung-Jue Bang
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sarbajit Mukherjee, Christos Fountzilas, Patrick M. Boland, Rohit Gosain, Kristopher Attwood, Wei Tan, Nikhil Khushalani, Renuka Iyer
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
Di Huang, Fan Zhang, Haitao Tao, Sujie Zhang, Junxun Ma, Jinliang Wang, Zhefeng Liu, Pengfei Cui, Shixue Chen, Ziwei Huang, Zhaozhen Wu, Lei Zhao, Yi Hu
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
Magdalena Olbryt, Wojciech Pigłowski, Marcin Rajczykowski, Aleksandra Pfeifer, Sebastian Student, Anna Fiszer-Kierzkowska
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
Luca Faloppi, Marco Puzzoni, Andrea Casadei Gardini, Nicola Silvestris, Gianluca Masi, Giorgia Marisi, Caterina Vivaldi, Cosmo Damiano Gadaleta, Pina Ziranu, Maristella Bianconi, Cristian Loretelli, Laura Demurtas, Eleonora Lai, Riccardo Giampieri, Eva Galizia, Paola Ulivi, Nicola Battelli, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi
High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
Ioannis A. Voutsadakis
c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis
Valentin Van den Bossche, Gaspard Jadot, Guillaume Grisay, Julien Pierrard, Natasha Honoré, Bénédicte Petit, David Augusto, Sébastien Sauvage, Jean-François Laes, Emmanuel Seront